Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Lie. No dilution in 2023. None.
A CAH can get federal money for that. Appropriation due in March if congress finally takes care of business. Both parties support the new stuff to make rural health care viable.
More good volume buying on deck. Feeling it.
dwindling
lolololol us guys don't have anything to do with it.
Feeding time at Seaworld.
There just isn't much upside left to be found on the big boards, growth companies with P/Es approaching 100, value companies in the 30 P/E range or higher. Time for the market to go OTC bottom fishing for bargains. Micro and macro are aligned for RNVA IMO. I still find it interesting that Forbes thought its readers (investors) might be interested in this article at this time. It sure takes the guess work out of CAH earnings estimates. https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=3d645fd56288
Current P/E under 2. Forward P/E as low as 1. RNVA has filed all the information investors need to realize how undervalued and oversold the stock is, that is IF they understand SEC insider trading regulations and RNVA's revenue flow from cost-based CAH reimbursements. There is just no reason left for the market to keep the price down any longer. None.
Let's see the .0002 ask. Will see much weaker resistance at .0002. That's obvious, all in the filings.
.0002 ask tomorrow? Signs are there.
Current at close of 2023.
With a P/E of 2 or less, the size of the OS shouldn't matter. $2.9 million debt reduction in 2023 reported already through Q3. Company guidance indicating strong Q4 against a lower cost of revenues ratio. Ripe for a breakout.
Current P/E = 2 or lower. It's that worthless.
News coming on:
- More restructuring of debt and "other securities" (happening as we speak)
- Jamestown reopening under the CAH model
- New CAH funding opportunites when congress finally gets off the crapper (March deadline under their latest CR).
Make that .00009 for those buybacks, not .0009. My bad.
End of the year, not due until April.
RNVA filings show the OS went unchanged from November 8 or earlier through January 11. The OS would have increased if the buyer had been an insider or commerial investor except maybe some commercial shorts buying to cover. Therefore, the January 11 amendment to the insider trading plan/prospectus indicates the corporation has been buying back preferred share conversions at .0009 or better. RNVA does not have to report corporate buybacks until April or when it is ready to announce them.
75% inpatient admissions increase in 2023, 8% outpatient increase with new Myrtle Recovery outpatient services only just beginning in Novemeber. When you factor what the Forbes article says about fixed cost reimbursement, you get $2-3 million earnings on $20-22 million revenues minimum. Cost of revenue ratio can only improve with revenue increases.
Current P/E @ .0001 between 1.5 and 2, maybe lower.
Minimum estimate: $2-3 million earnings on $20-22 million revenue. Certainty in forward earnings:
https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=45df4b676288
Forbes has taken an interest. There can't be many rural critical access hospital companies listed on any exchange. This article goes right at why I have so much confidence in RNVA forward revenue and earnings:
https://www.forbes.com/sites/gebai/2024/01/21/rural-urban-healthcare-access-gap-its-all-about-the-fixed-costs/?sh=f8412556288f
With you on that.
I've been playing with some numbers based on what we know (75% increase in inpatient admissions in 2023, swingbed revenues increasing, new Myrtle Recovery Center revenue beginning to come in against the costs that showed in Q3). The most conservative Q4 estimates have RNVA closing 2023 at over $20 million with a profit of at least two million. At .0001, that's a P/E of 2/1. At a bare minimum, we know we can $2 million to the bottom line in 2024 in interest savings from debt paid off or restructured plus Myrtle Recovery revenue increases through most if not all of the year, not to mention any continued growth from existing services.
We also know the OS has not changed for nearly three months and, according to the recently filed amendment to the insider trading plan/prospectus, the holder of those Series B Preferred Shares is no longer required to sell, but if they sell, they still have to sell at .00014 until the stock is uplisted to OTCQX or Nasdaq. That indicates that upon conversion the investor is holding common shares instead of selling and RNVA is kept a standing corporate buyback offer at .00014. Corporate buybacks are not subject to the SEC's insider trading plan reporting requirement. We're out of major .0001 sellers.
I have never been more confident in a 000 stock in my 30 years of f***king with them.
No red paint to close a holiday shortened week. Just my opinion, but I think next week will be big.
https://www.sec.gov/news/press-release/2023-234
Fox guarding the hen house, or someone who knows where the skeletons are buried?
So were tulip bulbs in the early 1600s. Wouldn't have bought those either if I had been around then.
Might get a short term bounce if your timing is right, but long term, obviously not. Oil companies have not added new refinery capacity for decades, because they know it would be a lousy long term investment.
I'm more concerned about the fallout when the bottom falls out of the crypto market. The bottom will fall out. It's inevitable. Tulip bulbs have more fundemental value.
Congress would have to do that. Don't fall for the propaganda funded by the same people who fund congressional campaigns of both parties. Blaming Gensler is too easy an out for them.
Too many in Congress don't have the balls to regulate markets and have fought Gensler on every regulation he does have the authority to implement, expecially regulations that protect small investors.
Gensler would shut down crypto if he had the legislative authority.
I have 30 years of experience and a growing list of successful OTC investments. Sorry that bores you. If staring at a ticker is entertaining to you, have at it. There are plenty of others to choose from.
All beginners are dumbasses. I was too. Some are willing and able to learn from others and from experience. Some just go on being dumbasses.
They should tell you how annoying your posts are, especially to those of us who post relevant, if not useful, information only to see it overposted by stupid stuff about a "ticker."
Nobody can tell you anything, because it's all way over your head.
Your posts are worthless.
So? Nothing to do with this situation. I read earnings reports. I never base my investment decisions on anyone's advice. At most, I might do my DD on a stock because isome4one I trust recommends it.
Funny how you didn't chime in when we saw the uptick on good volume this morning, only when trading slowed. "Pumpers?" What does that make you when you only chime in when "the ticker" gives you a chance to discourage buyers. The truth is, you don't have a clue why any ticker does what it does at any particular moment, because you don't understand the mechanics of it any more than you understand valuation. The OS has not changed for nearly three months. This is to educate you on why "the ticker" has done what it has been doing of late:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173657576
Your comparable is a fictional ticker from a movie? Good strategy.